Position in RLAY
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$49,918
+$18,835 QoQ
Shares Held
2,668
-14.6% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#210
of 256 holders
Holding Since
Sep 2021
12 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in RLAY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SIGNATUREFD, LLC holds $13,806,120 across 160 Biotechnology names. RLAY ranks #46 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,593 | $2,778,210 | |
| 2 | ARGX |
Argenx SE
|
2,075 | $1,925,122 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,756 | $1,094,936 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,063 | $621,024 | |
| 5 | INCY |
Incyte Corp
|
4,178 | $473,618 | |
| 6 | GMAB |
Genmab A/S
|
16,442 | $451,661 | |
| 7 | EXEL |
Exelixis, Inc.
|
7,184 | $390,881 | |
| 8 | PCVX |
Vaxcyte, Inc.
|
6,510 | $378,426 |
All Filings in RLAY
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $49,918 | 2,668 | Shares | Sole | 2026-07-24 | |
| 2026-03-31 | $31,083 | 3,124 | Shares | Sole | 2026-04-07 | |
| 2025-12-31 | $26,429 | 3,124 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $16,307 | 3,124 | Shares | Sole | 2025-10-21 | |
| 2025-06-30 | $10,809 | 3,124 | Shares | Sole | 2025-07-16 | |
| 2025-03-31 | $2,955 | 1,128 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $659 | 160 | Shares | Sole | 2025-02-10 | |
| 2024-06-30 | $4,068 | 624 | Shares | Sole | 2024-07-29 | |
| 2023-06-30 | $942 | 75 | Shares | Sole | 2023-08-01 | |
| 2023-03-31 | $8,860 | 538 | Shares | Sole | 2023-04-28 | |
| 2022-03-31 | $1,526 | 51 | Shares | Sole | 2022-05-02 | |
| 2021-09-30 | $15,607 | 495 | Shares | Sole | 2021-10-28 | |
| No filing history on record for this holder in this stock. | ||||||